Form 13-F position report

NEKTAR THERAPEUTICS

Reported by OppenheimerFunds Inc

NKTR CUSIP 640268108 Manager CIK 0000728889

Reported 24,400,000 shares, unchanged from the prior quarter.

Reported value -5.9%; share count 0.0% vs. the prior quarter.

Unchanged
% of reported 13F value 0.32% This manager · Q3 2014
Shares 24,400,000 Quarter-end amount reported
Reported value $294,508,000 Fair value at quarter end
Consecutive quarters held 6 Through Q3 2014

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2014-06-30 312808000
2014-09-30 294508000
2014-12-31 375100000
2015-03-31 286000000
2015-06-30 325260000
2015-09-30 289344000
2015-12-31 438157000
2016-03-31 357607000
2016-06-30 370056000
2016-09-30 429579000
2016-12-31 306852000
2017-03-31 563534000
2017-06-30 493779000
2017-09-30 594534000
2017-12-31 872185000
2018-03-31 1138631000
2018-06-30 564512000
2018-09-30 731658000
2018-12-31 568748000
2019-03-31 581377000

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for NEKTAR THERAPEUTICS held by OppenheimerFunds Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q1 2019 Reduced 17,302,891 -34 (0.0%) 0.72% $581,377,000 2019-05-13
Q4 2018 Added 17,302,925 +5,300,665 (44.2%) 0.81% $568,748,000 2019-02-11
Q3 2018 Added 12,002,260 +441,481 (3.8%) 0.85% $731,658,000 2018-11-13
Q2 2018 Added 11,560,779 +845,257 (7.9%) 0.67% $564,512,000 2018-08-13
Q1 2018 Reduced 10,715,522 -3,889,047 (-26.6%) 1.42% $1,138,631,000 2018-05-11
Q4 2017 Reduced 14,604,569 -10,167,661 (-41.0%) 1.05% $872,185,000 2018-02-12
Q3 2017 Reduced 24,772,230 -484,991 (-1.9%) 0.73% $594,534,000 2017-11-13
Q2 2017 Added 25,257,221 +1,246,403 (5.2%) 0.61% $493,779,000 2017-08-14
Q1 2017 Reduced 24,010,818 -997,502 (-4.0%) 0.68% $563,534,000 2017-05-11
Q4 2016 Added 25,008,320 +3,715 (0.0%) 0.39% $306,852,000 2017-02-14
Q3 2016 Reduced 25,004,605 -1,000,748 (-3.8%) 0.54% $429,579,000 2016-11-14
Q2 2016 Reduced 26,005,353 -2,408 (0.0%) 0.49% $370,056,000 2016-08-11
Q1 2016 Added 26,007,761 +4,386 (0.0%) 0.47% $357,607,000 2016-05-12
Q4 2015 Reduced 26,003,375 -427,994 (-1.6%) 0.56% $438,157,000 2016-02-05
Q3 2015 Added 26,400,000 +400,000 (1.5%) 0.39% $289,344,000 2015-11-06
Q2 2015 Unchanged 26,000,000 0 (0.0%) 0.37% $325,260,000 2015-08-06
Q1 2015 Added 26,000,000 +1,800,000 (7.4%) 0.32% $286,000,000 2015-05-15
Q4 2014 Reduced 24,200,000 -200,000 (-0.8%) 0.42% $375,100,000 2015-02-11
Q3 2014 Unchanged 24,400,000 0 (0.0%) 0.32% $294,508,000 2014-11-13
Q2 2014 Unchanged 24,400,000 0 (0.0%) 0.35% $312,808,000 2014-08-08
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

140 managers reported NEKTAR THERAPEUTICS for Q3 2014.

Managers reporting NEKTAR THERAPEUTICS in Q3 2014.
Manager Activity Shares Change % of reported 13F Reported value Tenure
OppenheimerFunds Inc This report Unchanged 24,400,000 0 0.32% $294,508,000 6 qtrs
PRIMECAP MANAGEMENT CO CA Added 18,137,786 +2,333,500 0.23% $218,923,000 6 qtrs
VANGUARD GROUP INC Added 8,119,924 +39,684 < 0.01% $98,008,000 6 qtrs
FIRST TRUST ADVISORS LP Added 6,136,021 +879,262 0.29% $74,062,000 6 qtrs
FEDERATED HERMES INC Reduced 5,871,200 -39,634 0.23% $70,865,000 6 qtrs
JPMorgan Chase & Co Added 4,428,675 +36,623 0.01% $53,453,000 6 qtrs
BlackRock Fund Advisors Reduced 4,306,099 -174,573 0.01% $51,975,000 6 qtrs
STATE STREET CORPORATION Reduced 4,163,202 -518,203 < 0.01% $50,246,000 6 qtrs
THE BANK OF NEW YORK MELLON CORPORATION Added 3,549,480 +2,583 0.01% $42,841,000 6 qtrs
BlackRock Institutional Trust Company N A Reduced 3,453,213 -76,349 < 0.01% $41,680,000 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2014
Filed
November 13, 2014
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
24,400,000
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.